Biovita - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 182,500 | 686,235 | 2,063,647 | 7,057,304 | 4,409,247 | 1,995,164 | 1,802,197 | 2,497,615 |
| Profit before tax | - | 15,365 | 36,290 | 1,552,169 | 424,289 | -274,989 | -257,933 | 100,266 |
| Net profit | 10,110 | 10,449 | 28,444 | 1,316,364 | 372,441 | -274,989 | -257,933 | 93,554 |
| Equity | -2,677 | 7,772 | 36,216 | 1,352,580 | 402,691 | 1,028,978 | 771,045 | 864,294 |
| Liabilities | 591,375 | 677,821 | 1,626,176 | 656,388 | 1,329,485 | 584,152 | 827,414 | 811,260 |
| Non-current assets | 384,714 | 345,390 | 243,751 | 353,536 | 440,834 | 444,218 | 545,450 | 574,287 |
| Current assets | 203,895 | 339,853 | 1,417,543 | 1,591,471 | 1,289,711 | 1,166,526 | 1,093,964 | 1,163,760 |
| Total assets | 588,609 | 685,243 | 1,661,294 | 1,945,007 | 1,730,545 | 1,610,744 | 1,639,414 | 1,738,047 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 293,122 | 222,672 | 124,181 |
| Social insurance contributions | - | - | - | - | - | 173,705 | 146,343 | 158,465 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +276.0% | +200.7% | +242.0% | -37.5% | -54.8% | -9.7% | +38.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 1.7% | 1.5% | 1.7% | 67.7% | 21.5% | -17.1% | -15.7% | 5.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 134.4% | 78.5% | 97.3% | 92.5% | -26.7% | -33.5% | 10.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.5% | 1.5% | 1.4% | 18.7% | 8.4% | -13.8% | -14.3% | 3.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 2.2% | 1.8% | 22.0% | 9.6% | -13.8% | -14.3% | 4.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 87.2 | 44.9 | 0.5 | 3.3 | 0.6 | 1.1 | 0.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 47,609 | 65,878 | 131,025 | 363,466 | 163,305 | 81,993 | 99,203 | 140,711 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biovita - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-04-20 | 2026-04-28 | 122.79 |
| 2026-02-18 | 2026-03-02 | 0.54 |
| 2025-05-16 | 2025-05-21 | 6.79 |
| 2025-02-18 | 2025-02-18 | 14124.08 |
| 2024-01-16 | 2024-01-24 | 3.62 |
| 2023-07-18 | 2023-07-18 | 2.10 |
| 2023-02-06 | 2023-02-14 | 3.46 |
| 2023-01-24 | 2023-02-03 | 3.46 |
Biovita - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-12-05 | 2025-12-05 | 2926.84 |
| 2025-03-04 | 2025-03-04 | 1447.89 |
| 2025-03-03 | 2025-03-03 | 1447.89 |
| 2025-03-02 | 2025-03-02 | 1446.72 |
| 2025-03-01 | 2025-03-01 | 1446.72 |
| 2025-02-28 | 2025-02-28 | 1446.72 |
| 2025-02-27 | 2025-02-27 | 0.0 |
| 2025-02-26 | 2025-02-26 | 0.0 |
| 2025-02-25 | 2025-02-25 | 0.0 |
| 2025-02-24 | 2025-02-24 | 0.0 |
| 2025-02-23 | 2025-02-23 | 0.0 |
| 2025-02-21 | 2025-02-22 | 0.0 |
| 2025-02-20 | 2025-02-20 | 0.0 |
| 2025-02-19 | 2025-02-19 | 0.0 |
| 2025-02-18 | 2025-02-18 | 0.0 |
| 2025-02-17 | 2025-02-17 | 0.0 |
| 2025-02-16 | 2025-02-16 | 0.0 |
| 2025-02-14 | 2025-02-15 | 0.0 |
| 2025-02-13 | 2025-02-13 | 0.0 |
| 2025-02-10 | 2025-02-12 | 0.0 |
| 2025-02-09 | 2025-02-09 | 0.0 |
| 2025-02-07 | 2025-02-08 | 0.0 |
| 2025-02-06 | 2025-02-06 | 0.0 |
| 2025-02-05 | 2025-02-05 | 0.0 |
| 2025-02-04 | 2025-02-04 | 0.0 |
| 2025-02-03 | 2025-02-03 | 0.0 |
| 2025-02-02 | 2025-02-02 | 0.0 |
| 2025-02-01 | 2025-02-01 | 0.0 |
| 2025-01-30 | 2025-01-31 | 0.0 |
| 2025-01-29 | 2025-01-29 | 0.0 |
| 2025-01-28 | 2025-01-28 | 0.0 |
| 2025-01-27 | 2025-01-27 | 0.0 |
| 2025-01-26 | 2025-01-26 | 0.0 |
| 2025-01-24 | 2025-01-25 | 0.0 |
| 2025-01-23 | 2025-01-23 | 0.0 |
| 2025-01-22 | 2025-01-22 | 0.0 |
| 2025-01-15 | 2025-01-21 | 0.0 |
| 2025-01-14 | 2025-01-14 | 1863.72 |
| 2025-01-13 | 2025-01-13 | 1863.72 |
| 2025-01-12 | 2025-01-12 | 1863.72 |
| 2025-01-10 | 2025-01-11 | 1863.72 |
| 2025-01-09 | 2025-01-09 | 1863.72 |
| 2025-01-01 | 2025-01-08 | 1861.72 |
| 2024-12-30 | 2024-12-31 | 1861.72 |
| 2024-12-29 | 2024-12-29 | 1861.72 |
| 2024-12-28 | 2024-12-28 | 1861.72 |
| 2024-12-27 | 2024-12-27 | 0.0 |
| 2024-12-26 | 2024-12-26 | 0.0 |
| 2024-12-25 | 2024-12-25 | 0.0 |
| 2024-12-24 | 2024-12-24 | 0.0 |
| 2024-12-23 | 2024-12-23 | 0.0 |
| 2024-12-22 | 2024-12-22 | 0.0 |
| 2024-12-20 | 2024-12-21 | 0.0 |
| 2024-12-19 | 2024-12-19 | 0.0 |
| 2024-12-18 | 2024-12-18 | 0.0 |
| 2024-12-17 | 2024-12-17 | 0.0 |
| 2024-12-16 | 2024-12-16 | 0.0 |
| 2024-12-15 | 2024-12-15 | 0.0 |
| 2024-12-13 | 2024-12-14 | 0.0 |
| 2024-12-12 | 2024-12-12 | 0.0 |
| 2024-12-11 | 2024-12-11 | 0.0 |
| 2024-12-10 | 2024-12-10 | 18.42 |
| 2024-12-08 | 2024-12-09 | 18.42 |
| 2024-12-06 | 2024-12-07 | 18.42 |
| 2024-12-05 | 2024-12-05 | 18.42 |
| 2024-12-04 | 2024-12-04 | 18.42 |
| 2024-12-03 | 2024-12-03 | 18.42 |
| 2024-12-01 | 2024-12-02 | 18.36 |
| 2024-11-29 | 2024-11-30 | 18.36 |
| 2024-11-28 | 2024-11-28 | 18.36 |
| 2024-11-27 | 2024-11-27 | 0.0 |
| 2024-11-26 | 2024-11-26 | 0.0 |
| 2024-11-25 | 2024-11-25 | 0.16 |
| 2024-11-24 | 2024-11-24 | 0.16 |
| 2024-11-20 | 2024-11-23 | 0.16 |
| 2024-11-18 | 2024-11-19 | 0.16 |
| 2024-11-17 | 2024-11-17 | 0.16 |
| 2024-10-16 | 2024-11-16 | 0.0 |
| 2024-10-14 | 2024-10-15 | 0.0 |
| 2024-10-10 | 2024-10-13 | 33.52 |
| 2024-10-09 | 2024-10-09 | 33.52 |
| 2024-10-07 | 2024-10-08 | 33.52 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biovita, UAB (code 304523645) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, revenue increased to €2.50M, up 38.6% year on year and 25.2% over two years. The company returned to profit, reporting net profit of €93.6K and a profit margin of 3.7%, after losses of €275.0K in 2023 and €257.9K in 2024. The 2024 decline in revenue to €1.80M was followed by a stronger 2025 recovery. At the end of 2025, total assets were €1.74M, equity €864.3K and liabilities €811.3K, with an equity ratio of 49.7% and debt-to-equity of 0.94. Efficiency indicators were solid, with ROE at 10.8%, ROA at 5.4% and asset turnover at 1.44x. Revenue per employee reached €146.9K, while profit per employee was €5.5K.